RxDoctor Payments Data

Minna Huang, MD

Nephrology · Upland, CANPI 1841447745

Payments from drug & device makers

$1,396in general payments, 2019–2025

Across 73 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$321
  • Akebia Therapeutics Inc$188
  • Bard Peripheral Vascular, Inc.$163
  • Aurinia Pharma U.S., Inc.$133
  • Travere Therapeutics, Inc.$105
  • Fresenius USA Marketing, Inc.$63
  • plus $423 from 15 others

What the payments were for

  • Food & beverage$1,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,396 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$792,450
Medicare patients
626
Services billed
9,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan15$186,728
FarxigaDapagliflozin Propanediol133$120,101
VeltassaPatiromer Calcium Sorbitex43$43,404
ProcritEpoetin Alfa31$37,670
JardianceEmpagliflozin17$17,199
Sevelamer Carbonate13$12,827
Sevelamer Hcl12$9,385
DapagliflozinDapagliflozin Propanediol11$7,707
Febuxostat29$6,391
Cinacalcet Hcl14$5,580
ProsolParenteral Amino Acid 20% No.128$3,687
Hydralazine Hcl234$2,998
Calcium Acetate47$2,338
Allopurinol210$2,148
Calcitriol114$1,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$321$120,101133 claims
Boehringer IngelheimJardiance$13$17,19917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,341 nephrology providers in California.

Other nephrology in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →